Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392491 | 0.94 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185581 | 0.94 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185641 | 0.94 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185652 | 0.94 | LTA4H (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL21361983 | 0.94 | HRH3 (0.38) | LTA4HHRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL22857557 | 0.92 | HRH3 (0.46) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL19185680 | 0.92 | LTA4H (0.44) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL22857504 | 0.91 | HRH3 (0.45) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL25064562 | 0.90 | LMNA (0.43) | LTA4HLMNAHRH3GNAI3GNAO1 | |
| SCHEMBL21725456 | 0.90 | HRH3 (0.41) | LTA4HHRH3GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282547-A1 | BENZIMIDAZOLE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC5, HDAC1, HDAC8 | LTA4H 2291/4885LMNA 978/4885HRH3 177/4885 |
| US-10736881-B2 | Benzimidazole derivatives: preparation and pharmaceutical applications | HDAC5, HDAC1, HDAC8 | LTA4H 2291/4885LMNA 978/4885HRH3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.